Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 10, 2002, Pages 544-549

  Kaya, Hakan ^a   Keung, Yi Kong ^a   Case, Douglas ^a   Cruz, Julia M ^a   Perry, James J ^a   Radford, James E ^a   Hurd, David D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

B lymphocytes; Low grade lymphoma; Monoclonal antibody therapy; Rituximab; Treatment failure

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CD20 ANTIGEN; CHLORAMBUCIL; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMMUNOGLOBULIN G1; MESNA; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PARACETAMOL; PREDNISONE; RITUXIMAB; UNINDEXED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KAPLAN MEIER METHOD; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 0036433170     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12434949     Document Type: Article

References (20)

1. Reff ME, Camer K, Chambers KS, et al. Depletion of B cells in vitro by chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
2. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997; 90:2188-2195.
3. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26(suppl 14): 66-73.
4. Greiner TC, Medeiros LJ, Jaffe ES. Non-Hodgkin's lymphomas. Cancer. 1995;75:370-380.
5. Lister TA. The management of follicular lymphoma. Ann Oncol. 1991;2:131-135.
6. Horning SJ. Natural history and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993;20:25-88.
7. Bierman PJ, Vose JM, Anderson JR, et al. High dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:445-450.
8. Haas R, Moos M, Mohle R, et al. High dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant. 1996;17:149-155.
9. Bastion Y, Brice P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood. 1995;86:3257-3262.
10. Morel P, Laporte JP, Noel MP, et al. Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases. Leukemia. 1995;9:576-582.
11. Vandenburghe E, Pearce R, Taghipour G, et al. Role of a second transplant in the management of poor prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. J Clin Oncol. 1997;15:1595-1600.
12. De Lima M, Van Besien KW, Giralt SA, et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997;19:121-127.
13. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study. Blood. 1998;92:1927-1932.
14. Tsai DE, Moore HCF, Hardy CL, et al. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant. 1999;24:521-526.
15. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986;5:255-260.
16. Stiff PJ. Blood and marrow transplantation in relapsed or refractory non-Hodgkin's lymphoma. Oncology. 1998;12:56-62.
17. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
18. Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am. 1997;11:937-947.
19. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphomas: half of patients respond to four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
20. Davis TA, Grillo-Lopez AJ, White CA, et al. Final report on the safety and efficacy of retreatment with rituximab for patients with non-Hodgkin's lymphoma. Blood. 1999;94:88a.